56 Recruiting Breast Cancer Phase 3 Clinical Trials
Active phase 3 studies for breast cancer enrolling across the USA. Verify eligibility and contact site coordinators.
All Breast Cancer studiesPhase 3 Studies for Breast Cancer
S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
📍 Regional Medical Center — Anniston, Alabama
View Study & Checklist ➔Prospective Randomized Study of Accelerated Radiation Therapy (PRART)
📍 New York Presbyterian Hospital at Lower Manhattan Cancer Center — New York, New York
View Study & Checklist ➔Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor
📍 Southern Highlands Cancer Centre — Bowral, New South Wales
View Study & Checklist ➔Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
📍 Novartis Investigative Site — Sint-Niklaas, Oost Vlaanderen
View Study & Checklist ➔A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
📍 Research Site — Gilbert, Arizona
View Study & Checklist ➔Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
📍 Marin Cancer Care, Inc — Greenbrae, California
View Study & Checklist ➔A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
📍 Research Site — Duarte, California
View Study & Checklist ➔Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
📍 Research Site — Anchorage, Alabama
View Study & Checklist ➔OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
📍 Clinical Trial Site — Tucson, Arizona
View Study & Checklist ➔A Study of the Use of Acellular Dermal Matrix for Breast Reconstruction
📍 Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
View Study & Checklist ➔DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
📍 UCLA Hematology Oncology — Los Angeles, California
View Study & Checklist ➔Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
📍 Memorial Sloan Kettering Basking Ridge (Consent and follow-up only) — Basking Ridge, New Jersey
View Study & Checklist ➔Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms
📍 Medicine Invention Design, Inc. - IORG0007849 - NPI 1023387701 — Rockville, Maryland
View Study & Checklist ➔A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
📍 Research Site — Daphne, Alabama
View Study & Checklist ➔Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer
📍 Providence St. Johns Health Center — Santa Monica, California
View Study & Checklist ➔S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
📍 Research Site — Duarte, California
View Study & Checklist ➔Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
📍 Ironwood Cancer & Research Centers - Chandler II — Chandler, Arizona
View Study & Checklist ➔Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
📍 Research Site — Casa Grande, Arizona
View Study & Checklist ➔A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
📍 Research Site — Boston, Massachusetts
View Study & Checklist ➔Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
📍 Southern Cancer Center, PC ( Site 8003) — Daphne, Alabama
View Study & Checklist ➔Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia
📍 Northwestern University — Chicago, Illinois
View Study & Checklist ➔Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
📍 BRCR Global — Plantation, Florida
View Study & Checklist ➔Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
📍 University of Alabama Birmingham — Birmingham, Alabama
View Study & Checklist ➔A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
📍 Cancer Blood and Specialty Clinic — Los Alamitos, California
View Study & Checklist ➔Relaxation for Women With Breast Cancer Undergoing Radiotherapy
📍 University of Texas MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔PALbociclib CoLlaborative Adjuvant Study
📍 University of South Alabama Mitchell Cancer Institute — Mobile, Alabama
View Study & Checklist ➔A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
📍 Beverly Hills Cancer Center — Beverly Hills, California
View Study & Checklist ➔Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
📍 Fairbanks Memorial Hospital — Fairbanks, Alaska
View Study & Checklist ➔A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
📍 Alabama Oncology — Birmingham, Alabama
View Study & Checklist ➔A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
📍 Ironwood Cancer & Research Centers — Chandler, Arizona
View Study & Checklist ➔Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
📍 The Kirklin Clinic of UAB Hospital — Birmingham, Alabama
View Study & Checklist ➔Effects, Metabolic Mechanisms and Predictors of Response to Acupuncture in Treating Psychoneurological Symptoms Among Breast Cancer Survivors
📍 University of Illinois Chicago College of Nursing, — Chicago, Illinois
View Study & Checklist ➔Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
📍 Mayo Clinic — Scottsdale, Arizona
View Study & Checklist ➔Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
📍 Clinical Trial Site — Hot Springs, Arkansas
View Study & Checklist ➔A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
📍 Southern Cancer Center, PC — Daphne, Alabama
View Study & Checklist ➔Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
📍 City of Hope - Phoenix — Goodyear, Arizona
View Study & Checklist ➔E-Mindfulness Approaches for Living After Breast Cancer
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
View Study & Checklist ➔Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
📍 University of Virginia — Charlottesville, Virginia
View Study & Checklist ➔Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer
📍 Baptist Health South Florida — Miami, Florida
View Study & Checklist ➔Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies
📍 Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
View Study & Checklist ➔Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
📍 Southern Cancer Center — Mobile, Alabama
View Study & Checklist ➔Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
📍 Rocky Mountain Cancer Centers - Aurora — Aurora, Colorado
View Study & Checklist ➔Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
📍 Mayo Clinic-Comprehensive Cancer Center-Breast Clinic — Phoenix, Arizona
View Study & Checklist ➔Topical Betamethasone Versus Moisturizer in Preventing Radiation Dermatitis in Large-Breasted Patients Treated in the Prone Position
📍 Odette Cancer Centre, Sunnybrook Health Sciences Centre — Toronto, Ontario
View Study & Checklist ➔A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
📍 Research Site — Largo, Florida
View Study & Checklist ➔Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
📍 Mount Sinai Medical Center — Miami Beach, Florida
View Study & Checklist ➔A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
📍 Research Site — Daphne, Alabama
View Study & Checklist ➔Two Versus One Week Breast Radiotherapy (RT)
📍 Brooklyn Methodist Hospital — New York, New York
View Study & Checklist ➔A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
📍 Ironwood Cancer & Research Centers — Chandler, Arizona
View Study & Checklist ➔